Thinly traded DBV Technologies (NASDAQ:DBVT) is up 17% premarket on modest volume following the resubmission of its U.S. marketing application for Viaskin Peanut for the treatment of peanut allergy in children ages 4-11 years.
The company withdrew its initial filing in December 2018 in order to generate additional data on manufacturing procedures and quality control.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.